A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Alabaster, Alabama, United States, 35007
- GSK Investigational Site
-
Jasper, Alabama, United States, 35501
- GSK Investigational Site
-
-
Arizona
-
Peoria, Arizona, United States, 85381 - 4828
- GSK Investigational Site
-
Phoenix, Arizona, United States, 85032
- GSK Investigational Site
-
-
California
-
Northridge, California, United States, 91325
- GSK Investigational Site
-
Oxnard, California, United States, 93030
- GSK Investigational Site
-
Redondo Beach, California, United States, 90277
- GSK Investigational Site
-
Santa Monica, California, United States, 90404
- GSK Investigational Site
-
-
Connecticut
-
Fairfield, Connecticut, United States, 06824
- GSK Investigational Site
-
-
Florida
-
Largo, Florida, United States, 33773
- GSK Investigational Site
-
Pembroke Pines, Florida, United States, 33026
- GSK Investigational Site
-
St. Petersburg, Florida, United States, 33701
- GSK Investigational Site
-
Tampa, Florida, United States, 33606
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- GSK Investigational Site
-
Elk Grove Village, Illinois, United States, 60007
- GSK Investigational Site
-
Flossmoor, Illinois, United States, 60422
- GSK Investigational Site
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- GSK Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- GSK Investigational Site
-
-
Maryland
-
Frederick, Maryland, United States, 21702
- GSK Investigational Site
-
-
Massachusetts
-
Newton, Massachusetts, United States, 02459
- GSK Investigational Site
-
Newton Center, Massachusetts, United States, 02459
- GSK Investigational Site
-
-
Michigan
-
Bingham Farms, Michigan, United States, 48025
- GSK Investigational Site
-
-
New Jersey
-
Edison, New Jersey, United States, 08818
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- GSK Investigational Site
-
Albuquerque, New Mexico, United States, 87108
- GSK Investigational Site
-
-
New York
-
Amherst, New York, United States, 14226
- GSK Investigational Site
-
New Hyde Park, New York, United States, 11040
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- GSK Investigational Site
-
-
Ohio
-
Concinnati, Ohio, United States, 45219
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- GSK Investigational Site
-
-
Pennsylvania
-
Lafayette Hill, Pennsylvania, United States, 19444
- GSK Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78756
- GSK Investigational Site
-
Plano, Texas, United States, 75093
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Washington
-
Walla Walla, Washington, United States, 99362
- GSK Investigational Site
-
Wenatchee, Washington, United States, 98801
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
 Inclusion criteria:
- Patients diagnosed with Restless Legs Syndrome (RLS).
- Patients diagnosed with RLS (symptoms include an overwhelming urge to move legs usually accompanied by uncomfortable sensations in the legs; usually occur at rest; worse during the evening or night and generally relieved, at least temporarily, by movement).
- Patients must give written informed consent prior to any specific study procedures.
Exclusion criteria:
- Patients with a primary sleep disorder other than RLS.
- Patients with symptoms of secondary RLS (i.e., renal failure, iron deficient anemia, pregnancy) or other movement disorders (i.e., Parkinson's Disease).
- Other inclusion or exclusion criteria to be evaluated by the physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average proportion of nights a subject has successfully treated his/her RLS symptoms after taking study medication for that night out of total number of nights dosed during the Double-Blind Phase.
Time Frame: 12 Weeks
|
12 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quality and satisfaction with sleep, severity of symptoms 2 hours post dosing with study medication.
Time Frame: 12 Weeks
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Dyskinesias
- Psychomotor Disorders
- Parasomnias
- Syndrome
- Psychomotor Agitation
- Restless Legs Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Ropinirole
Other Study ID Numbers
Other Study ID Numbers
- 100310
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Statistical Analysis Plan
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 100310Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.